List of Subsys drug patents

Subsys is owned by Btcp Pharma.

Subsys contains Fentanyl.

Subsys has a total of 10 drug patents out of which 0 drug patents have expired.

Subsys was authorised for market use on 04 January, 2012.

Subsys is available in spray;sublingual dosage forms.

Subsys can be used as treatment of pain.

The generics of Subsys are possible to be released after 27 April, 2030.

SUBSYS Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610523 BTCP PHARMA Sublingual fentanyl spray
Jan, 2027

(3 years from now)

US8835460 BTCP PHARMA Sublingual fentanyl spray and methods of treating pain
Jan, 2027

(3 years from now)

US9642797 BTCP PHARMA Sublingual fentanyl spray and methods of use to treat pain
Jan, 2027

(3 years from now)

US9289387 BTCP PHARMA Method of treating pain by administering sublingual fentanyl spray
Jan, 2027

(3 years from now)

US9642844 BTCP PHARMA Sublingual fentanyl spray
Jan, 2027

(3 years from now)

US8835459 BTCP PHARMA Sublingual fentanyl spray
Jan, 2027

(3 years from now)

US10016403 BTCP PHARMA Sublingual fentanyl spray
Jan, 2027

(3 years from now)

US9241935 BTCP PHARMA Sublingual fentanyl spray
Jan, 2027

(3 years from now)

US8486973 BTCP PHARMA Sublingual fentanyl spray
Apr, 2030

(7 years from now)

US8486972 BTCP PHARMA Sublingual fentanyl spray
Apr, 2030

(7 years from now)

Drugs and Companies using FENTANYL ingredient

Market Authorisation Date: 04 January, 2012

Treatment: Treatment of pain

Dosage: SPRAY;SUBLINGUAL

How can I launch a generic of SUBSYS before it's patent expiration?
More Information on Dosage

SUBSYS family patents

17

United States

3

Japan

3

European Union

2

Portugal

2

Poland

2

Australia

2

Denmark

2

Mexico

2

Spain

2

Canada

1

Slovenia

1

New Zealand

1

Cyprus

1

Norway

1

Russia

1

China

1

Brazil

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic